# Vir Biotechnology (VIR) — Analyst Forecast

VIR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/vir/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 10 | 0 | 0 | 10 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 7, 2026 | HC Wainwright & Co. | Maintained | Buy | $22.00 |
| Jun 11, 2026 | Morgan Stanley | Maintained | Overweight | $27.00 |
| Jun 3, 2026 | Leerink Partners | Maintained | Outperform | $21.00 |
| Mar 4, 2026 | HC Wainwright & Co. | Maintained | Buy | $20.00 |
| Feb 25, 2026 | Barclays | Maintained | Overweight | $30.00 |
| Feb 24, 2026 | Needham | Maintained | Buy | $18.00 |
| Feb 24, 2026 | Evercore ISI Group | Maintained | Outperform | $18.00 |
| Feb 24, 2026 | Morgan Stanley | Maintained | Overweight | $24.00 |
| Feb 9, 2026 | Needham | Maintained | Buy | $14.00 |
| Dec 30, 2025 | HC Wainwright & Co. | Maintained | Buy | $15.00 |
| Sep 15, 2025 | HC Wainwright & Co. | Maintained | Buy | $15.00 |
| Sep 3, 2025 | Evercore ISI Group | Initiated Coverage | Outperform | $12.00 |
| Aug 27, 2025 | B of A Securities | Upgraded | Neutral → Buy | $14.00 |
| Jul 11, 2025 | Raymond James | Initiated Coverage | Outperform | $12.00 |
| May 22, 2025 | Needham | Maintained | Buy | $14.00 |
| May 12, 2025 | Needham | Maintained | Buy | $14.00 |
| Apr 17, 2025 | Goldman Sachs | Maintained | Buy | $21.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Maintained | Buy | $110.00 |
| Feb 28, 2025 | Barclays | Maintained | Overweight | $31.00 |
| Feb 27, 2025 | Needham | Maintained | Buy | $19.00 |

## Frequently Asked Questions

### Is VIR a buy, sell, or hold?

Analysts covering Vir Biotechnology currently average a Buy rating: 10 buy, 0 hold and 0 sell, from 10 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on VIR?

On Oct 7, 2026, HC Wainwright & Co. maintained Vir Biotechnology at Buy with a price target of $22.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).